Phase 3 Readiness Tarsus plans a Phase 3 study for IRX-101 in early 2027 with results expected in 2028, signaling near-term clinical milestones that can drive conversations with CROs, contract manufacturers, patient advocacy groups, and potential strategic partners focused on ophthalmology trials.

Leadership Additions Recent appointments to the board and C-suite, including a new Chief Medical Officer and board member from Humana, indicate strengthened clinical governance and payer engagement, presenting entry points for payer-focused collaborations, clinical evidence generation, and market access discussions.

Growing Capital Significant capital raises and backing from Pharmakon Advisors, totaling well over two hundred million in financing, support ongoing R&D and commercial readiness, offering opportunities for co-investment, strategic partnerships, or joint development discussions with financial stakeholders.

Eye Care Focus Specialization in ophthalmology with XDEMVY and Demodex blepharitis campaigns positions Tarsus as a targeted partner for ophthalmology distributors, clinics, and eyewear/accessory players seeking to expand eye care product portfolios or integrate ocular therapeutics into practice.

Commercial Momentum Marketing initiatives like the Mite Party campaign for XDEMVY and existing revenue in the multi‑million range suggest readiness for market launch activities, enabling sales outreach to ophthalmology practices, payers, and health systems seeking innovative treatments with eye‑care differentiation.